Skip to main content

ORIGINAL RESEARCH article

Front. Pharmacol.
Sec. Ethnopharmacology
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1461447
This article is part of the Research Topic Plant Polyphenols: New Chemical and Pharmacological Approaches View all articles

Plukenetia volubilis Leaves as Source of anti-Helicobacter pylori agents

Provisionally accepted
Aditya Tan Aditya Tan 1Katia Scortecci Katia Scortecci 1,2,3Nathalia M. Cabral De Medeiros Nathalia M. Cabral De Medeiros 4Wirginia Kukula-Koch Wirginia Kukula-Koch 5Thomas J. Butler Thomas J. Butler 6Sinéad M. Smith Sinéad M. Smith 6Fabio Boylan Fabio Boylan 1,2,7*
  • 1 School of Pharmacy & Pharmaceutical Sciences, Faculty of Health Sciences, Trinity College Dublin, Dublin, County Dublin, Ireland
  • 2 Trinity Biomedical Sciences Institute, Faculty of Engineering, Mathematics and Science, Trinity College Dublin, Dublin, Ireland
  • 3 Departamento de Biologia Celular e Genética, Centro de Biociências, Universidade Federal do Rio Grande do Norte, Natal, Rio Grande do Norte, Brazil
  • 4 Department of Biology, State University of Paraíba, Campina Grande, Paraiba, Brazil
  • 5 Department of Pharmacognosy with the Laboratory of Medicinal Plants, Medical University of Lublin, Lublin, Lublin, Poland
  • 6 Department of Clinical Medicine, School of Medicine, Trinity College Dublin, Dublin, County Dublin, Ireland
  • 7 NatPro, Trinity College Dublin, Dublin, Ireland

The final, formatted version of the article will be published soon.

    This piece of work showcases the plant Plukenetia volubilis as a source of pharmacologically active polyphenols. These compounds were identified by High-Performance Liquid Chromatography coupled to Electrospray Ionisation and Quadrupole Time-of-Flight Mass Spectrometry (HPLC-ESI-QTOF-MS-MS) analysis of its water infusion. HSCCC from the ethyl acetate extract of the water infusion allowed for the separation and structure characterisation of Astragalin. In vitro testing with the water extract, the ethyl acetate extract and Astragalin demonstrated the anti-Helicobacter pylori activity using a clarithromycin-resistant clinical isolate (MIC = 0.53, 0.51 qnd 0.49 µg/mL, respectively). Moreover in-silico analysis for astragalin confirmed its strong interactions with target proteins for H. pylori.

    Keywords: Formal analysis, investigation, methodology, Writing -original draft. Fabio Boylan: Conceptualization, supervision, Writing -review & editing. Katia Scortecci: Investigation, Writing -original draft, Writing -review & editing. Nathalia Maira Cabral De Medeiros: Investigation

    Received: 08 Jul 2024; Accepted: 09 Oct 2024.

    Copyright: © 2024 Tan, Scortecci, Cabral De Medeiros, Kukula-Koch, Butler, Smith and Boylan. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Fabio Boylan, School of Pharmacy & Pharmaceutical Sciences, Faculty of Health Sciences, Trinity College Dublin, Dublin, Dublin 2, County Dublin, Ireland

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.